Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | CASP1 | P29466 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.57 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.57 |
| ▸ | PPARG | P37231 | 1/20 | 0.54 |
| ▸ | PPARA | Q07869 | 1/20 | 0.54 |
| ▸ | DGKA | P23743 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.51 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3487193 | 0.96 | DGKA (0.57) | PLA2G4ALMNAMEN1USP2ALDH1A1 | |
| SCHEMBL8000090 | 0.94 | LTA4H (0.57) | LMNAMEN1USP2ALDH1A1CYP3A4 | |
| SCHEMBL9258701 | 0.92 | RARB (0.54) | PLA2G4ALMNAMEN1USP2ALDH1A1 | |
| SCHEMBL7279461 | 0.90 | CYP4F2 (0.59) | LMNALTA4HL3MBTL1S1PR4S1PR1 | |
| SCHEMBL10929511 | 0.88 | CYP4Z1 (0.60) | LMNAALDH1A1CYP3A4PPARGPPARA | |
| SCHEMBL14534754 | 0.87 | LTA4H (0.56) | LMNAALDH1A1DGKALTA4HMAPT | |
| SCHEMBL14534753 | 0.87 | LTA4H (0.56) | LMNAALDH1A1DGKALTA4HMAPT | |
| SCHEMBL5498756 | 0.86 | P2RY10 (0.57) | LMNALTA4HL3MBTL1S1PR4S1PR1 | |
| SCHEMBL27313839 | 0.86 | THRB (0.57) | MEN1ALDH1A1KMT2ASMN1; SMN2PPARG | |
| SCHEMBL15922116 | 0.86 | PPARA (0.71) | PLA2G4ALMNAMEN1USP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10370344-B2 | 2-oxothiazole compounds and method of using same for chronic inflammatory disorders | AVEXXIN AS (NO) | 2019-08-06 | — | — | US | disclosed |
| US-10370344-B2 | 2-oxothiazole compounds and method of using same for chronic inflammatory disorders | AVEXXIN AS (NO) | 2019-08-06 | — | — | US | disclosed |
| EP-3431084-A1 | ANTIINFLAMMATORY 2-OXOTHIAZOLES | Avexxin AS (NO) | 2019-01-23 | — | — | EP | disclosed |
| EP-3431084-A1 | ANTIINFLAMMATORY 2-OXOTHIAZOLES | Avexxin AS (NO) | 2019-01-23 | — | — | EP | disclosed |
| US-20170166539-A1 | COMPOUND | AVEXXIN AS (NO) | 2017-06-15 | — | — | US | disclosed |
| US-20170166539-A1 | COMPOUND | AVEXXIN AS (NO) | 2017-06-15 | — | — | US | disclosed |
| US-20170166539-A1 | COMPOUND | AVEXXIN AS (NO) | 2017-06-15 | — | — | US | disclosed |
| US-9597318-B2 | 2-oxothiazole compounds and method of using same for chronic inflammatory disorders | AVEXXIN AS (NO) | 2017-03-21 | — | — | US | disclosed |
| US-9597318-B2 | 2-oxothiazole compounds and method of using same for chronic inflammatory disorders | AVEXXIN AS (NO) | 2017-03-21 | — | — | US | disclosed |
| US-9597318-B2 | 2-oxothiazole compounds and method of using same for chronic inflammatory disorders | AVEXXIN AS (NO) | 2017-03-21 | — | — | US | disclosed |
| CN-102647984-A | Anti-inflammatory 2-carbonylthiazoles and 2-carbonyloxazoles | AVEXXIN AS | 2012-08-22 | — | — | CN | disclosed |
| EP-2482815-A1 | ANTI INFLAMMATORY 2-OXOTHIAZOLES AND 2 -OXOOXAZOLES | Avexxin AS (NO) | 2012-08-08 | — | — | EP | disclosed |
| US-20110136879-A1 | COMPOUND | AVEXXIN AS (NO) | 2011-06-09 | — | — | US | disclosed |
| US-20110136879-A1 | COMPOUND | AVEXXIN AS (NO) | 2011-06-09 | — | — | US | disclosed |
| US-20110136879-A1 | COMPOUND | AVEXXIN AS (NO) | 2011-06-09 | — | — | US | disclosed |
| WO-2011039365-A1 | ANTI INFLAMMATORY 2-OXOTHIAZOLES AND 2 -OXOOXAZOLES | AVEXXIN AS (NO) | 2011-04-07 | — | — | WO | disclosed |
| WO-2011039365-A1 | ANTI INFLAMMATORY 2-OXOTHIAZOLES AND 2 -OXOOXAZOLES | AVEXXIN AS (NO) | 2011-04-07 | — | — | WO | disclosed |
| US-20100048727-A1 | PERFLUOROKETONE COMPOUNDS AND USES THEREOF | DAVID SAMUEL | 2010-02-25 | — | — | US | disclosed |
| EP-2139836-A1 | PERFLUOROKETONE COMPOUNDS AND USES THEREOF | The Royal Institution for the Advancement of Learning/McGill University (CA) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008122119-A1 | PERFLUOROKETONE COMPOUNDS AND USES THEREOF | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136879-A1 | COMPOUND | CBR1, CBR3, CCR1 | PLA2G4A 1999/4885LMNA 2116/4885MEN1 2321/4885 |
| US-20170166539-A1 | COMPOUND | CBR1, CBR3, CCR1 | PLA2G4A 2011/4885LMNA 2112/4885MEN1 2314/4885 |
| US-20100048727-A1 | PERFLUOROKETONE COMPOUNDS AND USES THEREOF | PLA2G1B, PLA2G4B, PLA2G2E | PLA2G4A 6/4885LMNA 937/4885MEN1 4014/4885 |
| US-10370344-B2 | 2-oxothiazole compounds and method of using same for chronic inflammatory disorders | CX3CR1, LTC4S, CBR1 | PLA2G4A 1174/4885LMNA 3006/4885MEN1 3221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.